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AbstrAct
We designed a large multicentric study to analyse the presence of MsrV particles in blood and csF of a 
large cohort of patients and controls from different European areas. 149 Ms patients and 153 neurological 
and healthy controls were selected from sardinia, spain, Northern-Italy and sweden. to avoid biological 
and inter-assay variability MsrV was detected within a single laboratory through nested and real-time 
PCR assays specific for pol and env genes. MsrV detection in blood and csF of Ms patients and controls in 
populations of different ethnicity gave significant differences (p<0.05 compared to neurological controls and 
<0.001 compared to healthy controls). The presence and viral load of MSRV are significantly associated with 
Ms as compared to neurological and healthy controls in all ethnic groups.
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INtroductIoN
Human endogenous retrovirus (HERV) family ac-
counts for at least 8% of the whole human genome. In gen-
eral, most of them are highly defective, but a few cases of 
complete proviruses have been described (1). The founder 
member of the human endogenous retroviruses (HERV)-
W family, originally discovered in multiple sclerosis (MS) 
patients (2, 3), has been designated as MS-associated ret-
rovirus (MSRV) (4, 5). RNA pol-sequences of MSRV have 
been confirmed in MS by subsequent independent studies 
(6-9), related to MS severity (10-12), and brain pathogenic-
ity (13). HERV-W gag and env protein have been shown to 
be increased in MS brains (14) and capable of activating 
Th1-like and innate immunity (15) and CNS demyelina-
tion (16). However, other studies suggest HERV-W/MSRV 
is only casually associated with MS (17, 18). This incon-
gruence may relate to variability in patients’ condition and 
population genetics, as well as intrinsic methodological 
differences (7, 11).
With the aim of providing additional evidence regard-
ing whether HERV-W/MSRV is associated with MS, we 
assayed for the presence of HERV-W/MSRV particles in 
blood and cerebrospinal fluid (CSF) of MS patients and 
controls in a very large cohort of patients and controls 
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from different European areas. Uniform patient selection 
and polarisation of the HERV-W/MSRV detection were 
adopted to limit biologic and methodological variables.
MAtErIAl ANd MEthods
One-hundred-forty-nine (149) MS patients and 153 
controls were selected from four distinct European areas: 
Sardinia (insular Italy), Ferrara (Northern Italy), Pamplo-
na (Spain) and Stockholm (Sweden), each with its own pe-
culiar mean MS prevalence rate (19, Figure 1). All donors 
gave informed consent to the study.
sardinians
Thirty-nine active untreated MS patients diagnosed 
according to the Poser criteria (20) (mean age 36.7 years; 
woman/man ratio 1.9) were selected; 39 age- and sex-
matched healthy subjects and 35 patients with other neuro-
logical diseases (OND) were also selected. OND controls 
included inflammatory post-infectious encephalomyelitis 
(2 patients), CNS vasculitis (3), and non inflammatory 
neurological diseases including migraine, compressive ra-
diculo-myelopathy, amyotrophic lateral sclerosis, heredo-
degenerative and toxic peripheral neuropathy.
Northern Italians (Ferrara)
CSF samples from 10 untreated MS patients (20) (4 
women, mean age 39.4, range 27-67) were collected at the 
Institute of Neurology, University of Ferrara. CSF samples 
from 20 OND patients (8 women, mean age 51.2 years) 
served as control including migraine, peripheral neuropa-
thy, amyotrophic lateralsclerosis, heredo-degenerative 
ataxia and 5 patients with CNS vasculitis.
Spanish (Pamplona, Navarra)
Fifty-nine blood samples from untreated relapsing and 
secondary progressive MS patients (20) (42 women, mean 
age 31.8) and 59 age-and sex-matched Spanish HC were 
collected at the Department of Neurology, University of 
Navarra.
Swedish (Stockholm)
Forty-nine patients (35 women, mean age 34 years) 
with acute monosymptomatic optic neuritis (ON) were 
consecutively enrolled at the Department of Ophthalmol-
ogy, Huddinge University Hospital. Every six months, 
all patients were subjected to detailed history and neuro-
ophthalmologic examination (11). Eleven such patients 
developed CDMS (20). HERV-W/MSRV from blood 
Figure 1. Study composition and mean MS prevalence rates (× 100,000 population17) in the four European areas under the present 
investigation.
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and CSF samples of this ON sub-cohort were analysed. 
Twenty-two non inflammatory OND individuals (mean 
age 49.5 years) were examined as control including head-
ache, Bell’s palsy, vertigo, hydrocephalus, polyneuropa-
thy and sensory disturbances of unknown origin.
detection of extracellular MsrV 
To avoid potentially biasing methodological differenc-
es between laboratories, all of the molecular assays were 
performed at the Department of Biomedical Sciences, 
University of Sassari. All samples coming from Stock-
holm, Pamplona, Ferrara and Neurology Clinic of Sassari 
were transported frozen, handled identically after freezing 
and tested concurrently under strict blind code.
Nested rt-Pcr of pol product. This method has 
been extensively reported in other publications from our 
group (7). 
real-time rt-Pcr: RNA extraction of 500 ml 
plasma/CSF samples and reverse transcription by us-
ing oligo-dT as primer PCR were carried out in a 25 ml 
volume containing 1X PCR buffer (Bio-Rad Hercules, 
CA), 1.5 mmol/L MgCl2, 200 nmol/L of each
 primer, 200 
mmol/L of dNTPs, and 100 nmol/L of TaqMan probes, 
1.25 units of iTAQ DNA polymerase (Bio-Rad Hercules, 
CA). The TaqMan assay amplification reactions were ini-
tially heated at 95°C for 3’ and then subjected to 50 cycles 
of 94°C for 15 seconds, 53°C for 30’’, and 60°C for 30’’ 
with iCycler iQ PCR Detection System (Bio-Rad, Her-
cules, CA). Primers pair ENVF (5’-GCCCCATCGTAT-
AGGAGTCTTTC-3’ bases 1188-1210) and ENVR (5’-
AGTGGCAGAGTGATAGCAGTTG-3’ bases 1253-1274) 
and TaqMan probes ENVP FAM-5’-CCCACCTTCACT-
GCCCACACCCAT-3’-TAMRA bases 1221-1244 (SIG-
MA Genosys Ltd UK). They were derived from the env 
gene for HERV-W/MSRV encoded RNA (GenBank ac-
cession number GI48949850). The RT-PCR products, 
(an 87-bp fragment) were cloned in Pcr 2.1 (Invitrogen 
Carlsbad, CA). Absolute copy number of plasmids were 
estimated according to the formula: n. molecules/µL= 
{plasmids concentration (g/l)/ [(fragment size “87 bp” + 
plasmid size “3931 bp”) × 660]} × 6,022 × 1023.
A standard graph of the cycle threshold (CT) was ob-
tained from serial plasmid dilutions (10 to 105 copies/
well). The CT values from unknown samples
 were plot-
ted on the respective standard curves, and the number 
of RNA env gene copies calculated. Each RNA extract 
and plasmid serial dilutions were analyzed in duplicate. 
To ensure that the PCR sensitivity did not differ between 
assays or change over time, and to evaluate the correct 
amplification, three HERV-W/MSRV positive samples 
were also tested during each amplification, starting from 
the same CT. To control for correct amplification and ret-
rotranscription, a HERV-W/MSRV positive sample was 
also submitted with each RNA extraction procedure, and 
the resulting extract amplified in duplicate. To confirm 
sample RNAs, we performed PCR amplification without 
RT reaction with pure mRNA samples, indicating that 
the prepared mRNA samples did not contain genomic 




The distribution of the nested RT-PCR was analyzed by 
using the χ2. Real-time data were managed by using mean 
and standard deviation. The unpaired T-test and Fisher’s 
exact test were used to compare different sample catego-
ries. Statistical significance was established for p value 
<0.05. A correlation study was performed to compare the 
viral load and the rate of HERV-W/MSRV+ of MS groups 
from different countries with the country-specific mean 
prevalence rate of MS. For this, the Pearson’s correlation 
coefficient (r) was calculated.
rEsults
detection of hErV-W/MsrV viraemia in Ms and con-
trols by nested Pcr
In the whole cohort, HERV-W/MSRV detection through 
nested RT-PCR (i.e. proportion of HERV-W/MSRV-posi-
tive cases) in blood and CSF of MS patients and controls 
gave significant differences. In particular, the percentage 
of HERV-W/MSRV+ MS patients was 71.4% in blood com-
pared to 17.3% in HC (p<0.001) and 40.3% in OND con-
trols (p<0.001). In the CSF, 74.5% MS and 45.6% OND 
had HERV-W/MSRV RNA (p<0.001; Table 1).
European populations were stratified according to 
their provenance. Among Sardinians the percentage of 
HERV-W/MSRV+ MS patients was 100% in blood com-
pared to 12.8% in HC (p<0.0001) and 42.8% in OND 
controls (p<0.0001). In Sardinian CSF, 82% MS and 
57% OND had HERV-W/MSRV RNA (p<0.001). Among 
Northern-Italians, 80% MS patients were MSRV+ in CSF 
compared to 40% OND (p=0.02). Among Swedish, the 
HERV-W/MSRV+ rate was 73.4% in blood and 67.3 in 
CSF of MS compared to 36.4% and 31.8%, respectively, 
of OND (p=0.0005). Among Spanish the rate of HERV-
W/MSRV+ in blood was 59.3% in MS and 20.3% in HC 
(p=0.01, Table 2).
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Evaluation of hErV-W/MsrV load in Ms and con-
trols by real-time rt-Pcr
In summary, HERV-W/MSRV detection through real-
time RT-PCR (i.e. number of HERV-W/MSRV copies/ml) 
in blood and CSF of MS patients and controls in the whole 
multicentric European series gave significant differences. 
In blood, MS patients produced an average 2527 ± 2376 
SD HERV-W/MSRV copies/ml in plasma compared to 256 
± 152 of OND controls (p<0.0001) and 327 ± 173 in HC. 
As for the CSF, MS patients produced an average 3190 ± 
1920 HERV-W/MSRV copies compared to OND (293 ± 
221; p<0.0001; Table 1).
European populations were therefore stratified ac-
cording to their provenance. Sardinian MS patients pro-
duced an average 2159 ± 2176 SD HERV-W/MSRV cop-
ies/ml in plasma relative to 180 ± 110 of OND controls 
(p<0.0001). Spanish MS patients produced 72.3 ± 44.4 
HERV-W/MSRV copies/ml in plasma compared to 15 ± 
2 of the HC (p=0.002). Swedish MS patients produced 
mean 419.4 ± 109.8 copies/ml in blood compared to 75.9 
± 18.9 of OND (p=0.0005). As for the CSF, Sardinian 
MS patients produced an average 2650 ± 1830 HERV-W/
MSRV copies compared to OND (162 ± 112; p<0.0001). 
In Northern-Italians an average 144.2 ± 39 CSF HERV-
W/MSRV copies were found in MS patients and 55.3 ± 
16.6 in OND controls (p=0.02). Among Swedish, 396.3 ± 
28.4 is the mean value in MS compared to 76.1 ± 16.9 in 
OND (p=0.04; Table 2).
table 1. Summary of MSRV detection through RT-PCR (A. proportion of MSRV-positive cases) 
and real-time RT-PCR (B. number of MSRV copies/ml) in blood and CSF of MS patients 
and controls in the European populations
A. Nested Pcr (pol) Ms oNd hc
Plasma cFs Plasma csF Plasma
All 105/147 73/98 23/57 37/81 17/98
(71.4%) (74.5%) (40.3%*) (45.6%*) (17.3%**)
b. real-time Pcr (env) Ms oNd hc
Plasma cFs Plasma csF Plasma
All 2527 3190 256** 293** 327**
p values for plasma and for CSF (MSRV viraemia in active MS vs. OND and HC)=*<0.05; **<0.001.
table 2. Details of the MSRV detection through nested RT-PCR (A. proportion of MSRV-positive 
cases) and real-time RT-PCR (B. number of MSRV copies/ml) in blood and CSF 
of MS patients and controls in the European populations
A. Nested Pcr (pol) Ms oNd hc
Plasma cFs Plasma csF Plasma
sardinia 39/39 (100%)*** 32/39 (82%)*** 15/35 (42.8%) 22/39 (57%)    5/39 (12.8%)
Northern Italy −    8/10 (80%)* −    8/20 (40%) −
spain 30/59 (59.3%)* − − − 12/59 (20.3%)
sweden 36/49 (73.4%)** 33/49 (67.3%)** 8/22 (36.4%) 7/22 (31.8%) −
b. real-time Pcr (env) Ms oNd hc
Plasma cFs Plasma csF Plasma
sardinia 2036*** 2650*** 180 162 312
Northern Italy − 144* − 55 −
spain 72** − − − 15
sweden 419** 396* 76 76 −
p values for plasma and for CSF (MSRV viraemia in active MS vs. OND and HC) are indicated in aster-
isks: *<0.05; **<0.001; ***<0.0001.
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dIscussIoN
Similar to other viruses, HERV-W/MSRV has been 
linked to MS by many groups, but only casually associ-
ated by others. Many biological and methodological biases 
might account for such variability (11). Therefore we de-
signed a multicentric-polarised study to report on the ac-
tual association between HERV-W/MSRV and MS.
In all samples that tested positive, we found the presence 
of both HERV-W/MSRV-env and -pol RNAs, regardless of 
the health/disease status of the individual, thus suggesting 
a co-ordinate accumulation of the two transcripts, as it oc-
curs for closely located genes. As observed in our previ-
ous work on the accumulation of MSRV/HERV-W gene 
transcripts in MS brains (21) the quantitative real-time and 
the semi-quantitative RT-PCR of env and pol genes gave 
comparable results. A statistically significant increase was 
observed in MS patients compared to controls, with re-
spect to both the percentage of HERV-W/MSRV positiv-
ity (nested RT-PCR) and the viral load (quantitative real 
time RT-PCR) in blood and, when available, in CSF. How-
ever, no intra-individual correlations between blood and 
CSF viral loads were found. We have previously seen by 
nested-RT-PCR that blood-MSRV+ patients may be CSF- 
and vice versa (7, 10). In the present study, the quantitative 
analysis (real-time) indicates that the viral load of MSRV 
is also different between distinct compartments in the 
same individual.
Overall, our data indicate that in distinct ethnic groups 
HERV-W/MSRV release is significantly elevated in MS as 
compared to other controls. In the recent past (7) we found 
that MSRV positivity in OND was significantly higher 
(63.6% in blood) in patients with inflammatory OND as 
compared to patients with non–inflammatory OND (33%, 
p<0.001 in blood). This suggests that MSRV is not specific 
for MS, despite its acronym. Therefore, HERV-W/MSRV 
appears to be more suggestive of inflammation rather than 
merely MS. At the etiopathogenic level, the higher release 
of the virus in MS patients does not provide definitive evi-
dence that HERV-W/MSRV release is a causal event, nor 
even a secondary pathogenic co-factor; on the contrary, it 
may reflect a generic predisposition to it: in fact, HERV-
W/MSRV pol gene expression is found in 69% sera from 
South-African MS patients, absent in serum of 39 unre-
lated HC (p<0.001) but present in 70% of the unaffected 
close relatives of the MS patients (6). Alternatively, HERV-
W/MSRV production might reflect an indirect, coinciden-
tal effect of the dysfunctional inflammatory-degenerative 
cascade occurring in MS (22). Th1 detrimental cytokines 
exert a HERV-W/MSRV-releasing effect on HERV-W/
MSRV+ monocytes in vitro, whilst IFN-β actively down-
modulates its expression (23). Perhaps due to this modula-
tion, the pro-inflammatory cytokine pattern which devel-
ops in MS may up-modulate HERV-W/MSRV expression, 
thus allowing speculation on an immune-mediated HERV-
W/MSRV release rather than a primary causative effect of 
HERV-W/MSRV in MS. 
Some other points also deserve the same interpreta-
tive caution. One is the question of what factors might 
explain the geographical-ethnic differences in the preva-
lence of MSRV in MS populations versus control groups. 
It is known that genetic factors play a pivotal role in MS. 
One could argue that, as Sardinia is a small geographically 
isolated island with a very genetically isolated population, 
some unknown genetic selective pressures could have 
forced the Sardinian genome to contain thousands copies 
of MSRV. However, preferential circulation of MSRV in 
geographically closed population such as Sardinians can-
not be excluded.
The clinical groups were dissimilar in terms of sample 
extension which may rise concerns when making com-
parisons between countries. However, even though patient 
selection was not uniform in terms of absolute numbers, 
the study was set to ensure that all samples were collected 
and stored at the same time and under similar conditions. 
Although RNA is prone to degradation, sample transpor-
tation has not been likely to have influenced the results 
since all samples contained 200U of RNAse Inhibitor and 
were carefully shipped.
In conclusion, the present study confirms HERV-W/
MSRV to be an important marker of the ongoing process 
occurring in MS. With its well known pathogenic potential 
(1) and its association with a more severe MS course (10-
12), HERV-W/MSRV may represent an interesting issue 
for future patho-physiological and therapeutical studies.
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